Chemicals and Raw Material for Medicines Buyer and Importer

European Pharmaceutical Review is the leading publication for up-to-the-minute information on all aspects of drug analysis, formulation, delivery, manufacturing and regulation. Published bi-monthly, each issue delivers high-level technical and business contributions from the world’s leading pharmaceutical scientists and business experts, coupled with a variety of features including interviews, updates and profiles. Providing the industry with cutting-edge facts and analysis for two decades, European Pharmaceutical Review remains faithful to the key aspects that serve its existing stakeholders so well. It delivers insights into current and emerging technologies, contributions from recognised figures in the life science community, and quality presentation that makes every issue a reference tool for laboratories and offices across the world. Choose your free membership option and experience for yourself why thousands of pharmaceutical and life science professionals have already joined the European Pharmaceutical Review community. Membership entitles to you a free subscription to our print and/or digital magazine, as well as unrestricted access to our website, offering the latest articles, application notes and webinars. Readership & circulation European Pharmaceutical Review is regularly distributed to 12,000 senior managers and key decision-makers in the pharmaceutical, life sciences and drug discovery industries predominantly across Europe, but also with a guaranteed circulation of 1,000 in the US. Typical job titles include Managing Directors, Procurement Directors, Heads of R&D, Senior Scientists, Laboratory Managers, Process Engineers, Chief Engineers, Production Directors, Plant Managers, Product Managers, Quality Assurance Managers and Quality Control Managers. Pharmaceutical manufacturers are a core component of our readership. Passed down through the management chain, we estimate that the total readership of European Pharmaceutical Review is 40,662 for each issue. This represents a highly targeted advertising opportunity for companies who wish to influence the key decision-makers in what is a vitally important industry.ufacturing and regulation. Published bi-monthly, each issue delivers high-level technical and business contributions from the world’s leading pharmaceutical scientists and business experts, coupled with a variety of features including interviews, updates and profiles. Providing the industry with cutting-edge facts and analysis for two decades, European Pharmaceutical Review remains faithful to the key aspects that serve its existing stakeholders so well. It delivers insights into current and emerging technologies, contributions from recognised figures in the life science community, and quality presentation that makes every issue a reference tool for laboratories and offices across the world. Choose your free membership option and experience for yourself why thousands of pharmaceutical and life science professionals have already joined the European Pharmaceutical Review community. Membership entitles to you a free subscription to our print and/or digital magazine, as well as unrestricted access to our website, offering the latest articles, application notes and webinars. Readership & circulation European Pharmaceutical Review is regularly distributed to 12,000 senior managers and key decision-makers in the pharmaceutical, life sciences and drug discovery industries predominantly across Europe, but also with a guaranteed circulation of 1,000 in the US. Typical job titles include Managing Directors, Procurement Directors, Heads of R&D, Senior Scientists, Laboratory Managers, Process Engineers, Chief Engineers, Production Directors, Plant Managers, Product Managers, Quality Assurance Managers and Quality Control Managers. Pharmaceutical manufacturers are a core component of our readership. Passed down through the management chain, we estimate that the total readership of European Pharmaceutical Review is 40,662 for each issue. This represents a highly targeted advertising opportunity for companies who wish to influence the key decision-makers in what is a vitally important industry. Show More